

In the Claims:

Please amend the claims as follows:

61
15. (Amended) A method of treating Type I diabetes mellitus in a mammal comprising administering to said mammal an effective amount of an insulin and an effective amount of a glucagon-like peptide 1 (7-36) amide agonist, wherein said glucagon-like peptide 1 (7-36) amide agonist delays gastric emptying and wherein said glucagon-like peptide 1 (7-36) amide agonist is administered orally.

62
18. (Amended) A method according to any of claims 15-17 wherein said glucagon-like peptide 1 (7-36) amide agonist is glucagon-like peptide 1 (7-37) [(7-36)].

63
20. (Amended) A method of treating Type I diabetes mellitus in a mammal comprising administering an effective amount of a glucagon-like peptide 1 (7-36) amide agonist, wherein said glucagon-like peptide 1 (7-36) amide agonist delays gastric emptying and wherein said glucagon-like peptide 1 (7-36) amide agonist is administered orally.

64
23. (Amended) A method according to any of claims 20-22 wherein said glucagon-like peptide 1 (7-36) amide agonist is glucagon-like peptide 1 (7-37) [(7-36)].

65
25. (Amended) A method of treating Type I diabetes mellitus in a mammal comprising administering to said

B5
mammal an effective amount of an insulin and an effective amount of a glucagon-like peptide 1 (7-36) amide agonist, wherein said glucagon-like peptide 1 (7-36) amide agonist delays gastric emptying and wherein said glucagon-like peptide 1 (7-36) amide agonist is administered nasally.

B6
28. (Amended) A method according to any of claims 25-27 wherein said glucagon-like peptide 1 (7-36) amide agonist is glucagon-like peptide 1 (7-37) [(7-36)].

B7
30. (Amended) A method of treating Type I diabetes mellitus in a mammal comprising administering an effective amount of a glucagon-like peptide 1 (7-36) amide agonist, wherein said glucagon-like peptide 1 (7-36) amide agonist delays gastric emptying and wherein said glucagon-like peptide 1 (7-36) amide agonist is administered nasally.

B8
33. (Amended) A method according to any of claims 30-32 wherein said glucagon-like peptide 1 (7-36) amide agonist is glucagon-like peptide 1 (7-37) [(7-36)].

After the claims, please add Exhibit A as the Abstract.

REMARKS

Applicant has amended the claims solely in order to expedite prosecution of the case. As set forth above, Applicant has included the phrase "wherein said glucagon-